Palvella Therapeutics, Inc. (PVLA)
97.50
-1.49
(-1.51%)
USD |
NASDAQ |
Dec 10, 16:00
97.50
0.00 (0.00%)
After-Hours: 16:11
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.154B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 29.83 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4142 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA. |
| URL | http://www.palvellatx.com |
| Investor Relations URL | https://ir.palvellatx.com/ |
| HQ State/Province | Pennsylvania |
| Sector | |
| Industry | |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA. |
| URL | http://www.palvellatx.com |
| Investor Relations URL | https://ir.palvellatx.com/ |
| HQ State/Province | Pennsylvania |
| Sector | |
| Industry | |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |